 DOWNLOAD CORPORATE FACT SHEET (PDF) |
| Press Releases 2010 | |
June 7, 2010 |
|
 |
Cytheris Closes €12 Million ($15 Million) Series D Financing |
 |
|
|
March 16, 2010 |
|
|
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis |
|
|
|
February 2, 2010 |
|
|
Cytheris Announces Notice of Allowance for U.S. Patent Covering the Preparation and Uses of its Glycosylated Recombinant Human Interleukin-7 (CYT107) |
|
|
|
January 12, 2010 |
|
|
Cytheris Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy |
|
|
